Allogene Therapeutics Inc... (ALLO)
NASDAQ: ALLO
· Real-Time Price · USD
1.10
0.03 (2.80%)
At close: Aug 15, 2025, 3:59 PM
1.12
1.36%
After-hours: Aug 15, 2025, 07:51 PM EDT
Allogene Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | 22K | -22K | n/a | 22K | 30K | 121K | 148K | 212K | 243K | 247K | 247K | 205K | 38.49M | 38.44M | 38.39M | 38.34M |
Cost of Revenue | 9.54M | 13.18M | 13.64M | 13.88M | 14.25M | 10.6M | 7.05M | 3.57M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -9.54M | -13.18M | -10.06M | -6.87M | -7.22M | -3.55M | -3.54M | -3.45M | 148K | 212K | 243K | 247K | 247K | 205K | 38.49M | 38.44M | 38.39M | 38.34M |
Operating Income | -254.27M | -268.89M | -273.2M | -297.88M | -289.11M | -298.21M | -327.8M | -339M | -358.5M | -354.55M | -335.45M | -312.97M | -308.15M | -302.58M | -255.79M | -251.26M | -241.63M | -233.76M |
Interest Income | 15.25M | 20.24M | 20.15M | 23.39M | 22.89M | 21.68M | 18.31M | 14.8M | 9.6M | 6.13M | 4.57M | 2M | 1.39M | 1.7M | 1.71M | 3.09M | 4.7M | 6.41M |
Pretax Income | -236.47M | -251.88M | -257.15M | -286.91M | -282.9M | -295.78M | -330.74M | -336.33M | -357.19M | -352.75M | -332.63M | -312.65M | -307.69M | -303.84M | -257M | -250.71M | -238.72M | -228.76M |
Net Income | -236.91M | -252.32M | -257.59M | -287.27M | -283.27M | -296.14M | -331.11M | -336.33M | -357.19M | -352.75M | -332.63M | -312.65M | -307.69M | -303.84M | -257M | -250.71M | -238.72M | -228.76M |
Selling & General & Admin | 61.12M | 62.93M | 65.2M | 66.91M | 67.62M | 70.06M | 71.67M | 75.45M | 77.31M | 78.29M | 79.31M | 78.26M | 78.37M | 77.64M | 74.11M | 71.28M | 68.9M | 65.98M |
Research & Development | 180.04M | 190.24M | 192.3M | 201.99M | 203.25M | 214.94M | 242.91M | 263.67M | 281.34M | 276.47M | 256.39M | 234.95M | 230.03M | 225.15M | 220.18M | 218.42M | 211.12M | 206.13M |
Other Expenses | 13.11M | 15.72M | 15.72M | 28.96M | 14.66M | 9.67M | 9.67M | -3.57M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 254.27M | 268.89M | 273.22M | 297.86M | 285.53M | 294.66M | 324.26M | 335.55M | 358.64M | 354.76M | 335.69M | 313.21M | 308.4M | 302.79M | 294.28M | 289.7M | 280.02M | 272.11M |
Interest Expense | 63K | 331K | 181K | 100K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 197.46M | 268.89M | 273.22M | 297.86M | 289.11M | 298.24M | 327.83M | 339.12M | 358.64M | 354.76M | 335.69M | 313.21M | 308.4M | 302.79M | 294.28M | 289.7M | 280.02M | 272.11M |
Income Tax Expense | 443K | 443K | 443K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 218.93M | 215.36M | 210.57M | 209.19M | 190.03M | 169.13M | 168.34M | 167.65M | 146.8M | 144.56M | 144.15M | 143.66M | 143.38M | 141.36M | 139.17M | 137.03M | 134.83M | 132.16M |
Shares Outstanding (Diluted) | 218.93M | 215.36M | 210.57M | 209.19M | 190.03M | 169.13M | 168.34M | 167.65M | 146.8M | 144.56M | 144.15M | 143.66M | 143.38M | 141.36M | 139.17M | 137.03M | 134.83M | 132.16M |
EPS (Basic) | -1.11 | -1.23 | -1.33 | -1.56 | -1.61 | -1.8 | -2.1 | -2.25 | -2.46 | -2.44 | -2.32 | -2.2 | -2.19 | -2.2 | -1.89 | -1.88 | -1.83 | -1.83 |
EPS (Diluted) | -1.11 | -1.23 | -1.33 | -1.56 | -1.61 | -1.8 | -2.1 | -2.25 | -2.46 | -2.44 | -2.32 | -2.2 | -2.19 | -2.2 | -1.89 | -1.88 | -1.83 | -1.83 |
EBITDA | -232.47M | -238.45M | -243.41M | -255.68M | -251.41M | -265.51M | -299.65M | -324.5M | -344.42M | -340.44M | -321.15M | -297.5M | -294.21M | -290.36M | -245.34M | -235.18M | -226.07M | -218.28M |
EBIT | -185.19M | -251.63M | -257.05M | -269.5M | -265.59M | -279.69M | -313.78M | -338.29M | -358.5M | -354.55M | -335.45M | -312.97M | -308.15M | -302.58M | -255.79M | -243.24M | -233.61M | -225.74M |
Depreciation & Amortization | 9.54M | 13.18M | 13.64M | 13.88M | 14.25M | 14.25M | 14.2M | 13.79M | 14.08M | 14.11M | 14.29M | 15.47M | 13.94M | 12.23M | 10.45M | 8.06M | 7.54M | 7.46M |